Show simple item record

dc.contributor.authorDore, GJ
dc.contributor.authorFeld, JJ
dc.contributor.authorThompson, A
dc.contributor.authorMartinello, M
dc.contributor.authorMuir, AJ
dc.contributor.authorAgarwal, K
dc.contributor.authorMullhaupt, B
dc.contributor.authorWedemeyer, H
dc.contributor.authorLacombe, K
dc.contributor.authorMatthews, GV
dc.contributor.authorSchultz, M
dc.contributor.authorKlein, M
dc.contributor.authorHezode, C
dc.contributor.authorMercade, GE
dc.contributor.authorKho, D
dc.contributor.authorPetoumenos, K
dc.contributor.authorMarks, P
dc.contributor.authorTatsch, F
dc.contributor.authorDos Santos, AGP
dc.contributor.authorGane, E
dc.contributor.authorTrinh, R
dc.contributor.authorErratt, A
dc.contributor.authorMercade, GE
dc.contributor.authorQuiene, S
dc.contributor.authorShaw, I
dc.contributor.authorFilep, E
dc.contributor.authorMartinello, M
dc.contributor.authorPetoumenos, K
dc.contributor.authorRoberts, S
dc.contributor.authorFoster, G
dc.contributor.authorCurry, M
dc.contributor.authorWarlow, J
dc.contributor.authorMauss, S
dc.contributor.authorStedman, C
dc.contributor.authorVachon, M-L
dc.contributor.authorChristensen, S
dc.contributor.authorMuir, A
dc.contributor.authorSchultz, M
dc.contributor.authorBaker, D
dc.contributor.authorRamji, A
dc.contributor.authorCornberg, M
dc.contributor.authorBloch, M
dc.contributor.authorHezode, C
dc.contributor.authorBourliere, M
dc.contributor.authorLacombe, K
dc.contributor.authorSemmo, N
dc.contributor.authorAgarwal, K
dc.contributor.authorCannon, M
dc.contributor.authorTam, E
dc.contributor.authorKlein, M
dc.contributor.authorJacobson, I
dc.contributor.authorShaw, D
dc.contributor.authorLevin, J
dc.contributor.authorTsoi, K
dc.contributor.authorCooke, G
dc.contributor.authorThompson, A
dc.contributor.authorMatthews, G
dc.contributor.authorFeld, J
dc.contributor.authorBorgia, SM
dc.contributor.authorBaumgarten, A
dc.date.accessioned2020-12-14T05:20:14Z
dc.date.available2020-12-14T05:20:14Z
dc.date.issued2020-03-01
dc.identifierpii: S0168-8278(19)30612-9
dc.identifier.citationDore, G. J., Feld, J. J., Thompson, A., Martinello, M., Muir, A. J., Agarwal, K., Mullhaupt, B., Wedemeyer, H., Lacombe, K., Matthews, G. V., Schultz, M., Klein, M., Hezode, C., Mercade, G. E., Kho, D., Petoumenos, K., Marks, P., Tatsch, F., Dos Santos, A. G. P. ,... Baumgarten, A. (2020). Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial. JOURNAL OF HEPATOLOGY, 72 (3), pp.431-440. https://doi.org/10.1016/j.jhep.2019.10.010.
dc.identifier.issn0168-8278
dc.identifier.urihttp://hdl.handle.net/11343/253911
dc.description.abstractBACKGROUND & AIMS: Direct-acting antiviral (DAA) therapy for HCV has high efficacy and limited toxicity. We hypothesised that the efficacy of glecaprevir-pibrentasvir for chronic HCV with a simplified treatment monitoring schedule would be non-inferior to a standard treatment monitoring schedule. METHODS: In this open-label multicentre phase IIIb trial, treatment-naïve adults with chronic HCV without cirrhosis were randomly assigned (2:1) to receive glecaprevir-pibrentasvir 300 mg-120 mg daily for 8 weeks administered with a simplified or standard monitoring strategy. Clinic visits occurred at baseline and post-treatment week 12 in the simplified arm, and at baseline, week 4, week 8, and post-treatment week 12 in the standard arm. Study nurse phone contact occurred at week 4 and week 8 in both arms. Participants requiring adherence support were not eligible, including those reporting recent injecting drug use. The primary endpoint was sustained virological response at post-treatment week 12 (SVR12), with a non-inferiority margin of 6%. RESULTS: Overall, 380 participants (60% male, 47% genotype 1, 32% genotype 3) with chronic HCV were randomised and treated with glecaprevir-pibrentasvir in the simplified (n = 253) and standard (n = 127) arms. In the intention-to-treat population, SVR12 was 92% (95% CI 89%-95%) in the simplified and 95% (95% CI 92%-99%) in the standard arm (difference between arms -3.2%; 95% CI -8.2% to 1.8%) and did not reach non-inferiority. In the per-protocol population, SVR12 was 97% (95% CI 96%-99%) in the simplified and 98% (95% CI 96%-100%) in the standard arm. No treatment-related serious adverse events were reported. CONCLUSIONS: In patients with chronic HCV infection without cirrhosis, treatment with glecaprevir-pibrentasvir was safe and effective. In comparison to standard monitoring, a simplified monitoring schedule did not achieve non-inferiority. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT03117569. LAY SUMMARY: Direct-acting antiviral (DAA) therapy for hepatitis C is highly effective and well tolerated. The SMART-C randomised trial evaluated an 8-week regimen of glecaprevir-pibrentasvir for hepatitis C treatment, using a simplified monitoring schedule that included no pathology tests or clinic visits during treatment. This simplified strategy produced a high cure rate (92%), but this was not equivalent to the standard monitoring schedule cure rate (95%).
dc.languageEnglish
dc.publisherELSEVIER
dc.titleSimplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial
dc.typeJournal Article
dc.identifier.doi10.1016/j.jhep.2019.10.010
melbourne.affiliation.departmentMedicine (St Vincent's)
melbourne.affiliation.facultyMedicine, Dentistry & Health Sciences
melbourne.source.titleJournal of Hepatology
melbourne.source.volume72
melbourne.source.issue3
melbourne.source.pages431-440
melbourne.elementsid1420440
melbourne.openaccess.urlhttps://www.zora.uzh.ch/id/eprint/183271/1/SMART-C_revised_manuscript_Aug_2019_%28clean%29.pdf
melbourne.openaccess.statusAccepted version
melbourne.contributor.authorThompson, Alexander
dc.identifier.eissn1600-0641
melbourne.accessrightsAccess this item via the Open Access location


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record